| II-42 Clémence Pouzin Modelling approaches to support tusamitamab ravtansine (DM4 anti-CEACAM5 antibody-drug conjugate) drug development. Wednesday 15:10-16:40 |
| II-42 Clémence Pouzin Modelling approaches to support tusamitamab ravtansine (DM4 anti-CEACAM5 antibody-drug conjugate) drug development. Wednesday 15:10-16:40 |